Texas Tribune: The Rio Grande Valley is at the epicenter of an Alzheimer’s spike among Latinos and is now the focus of new research efforts
February 4, 2023
Sudha Seshadri, MD, founding director of the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases at UT Health San Antonio, speaks to the spike of Alzheimer’s disease in South Texas and how in partnership with the University of Texas Rio Grande Valley, the institute is looking at why there are so many cases in South […]
January 30, 2023
Study will evaluate senolytics — drugs that clear defective ‘zombie’ cells A clinical trial conducted at UT Health San Antonio aims to “stomp” out Alzheimer’s disease. Clearing old, damaged “zombie” cells from the brain may be one way to do it. The study, called SToMP-AD (Senolytic Therapy to Modulate the Progression of Alzheimer’s Disease), seeks 21 San […]
January 26, 2023
Deep brain stimulation, continuous levodopa infusion among topics Four fellowship-trained movement disorders neurologists from UT Health San Antonio will give talks Friday (Jan. 27) at the Parkinson’s Foundation Tri-State Symposium. These physicians will discuss the newest developments in research and clinical trials of Parkinson’s disease and other disorders. The symposium, free and open to the […]
January 11, 2023
Statement from the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases at UT Health San Antonio about a timely topic in the news: The U.S. Food and Drug Administration on Friday, Jan. 6, 2023, approved lecanemab, a drug that targets the basic pathophysiology of Alzheimer’s disease. The FDA action is an “accelerated approval” of the […]
Texas Public Radio: Clinical trial for first Alzheimer’s drug with effect on cognitive decline looks for South Texas recruits
December 9, 2022
Arash Salardini, MD, neurologist at the Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, was interviewed for this story on Texas Public Radio (KSTX) on a clinical trial in South Texas for a drug to treat cognitive decline. The clinical trial, AHEAD 3-45, is to assess whether IV infusions of the antibody (lecanemab) can delay cognitive […]
Can Alzheimer’s disease be delayed or stopped before the symptoms begin? A new clinical trial strives to find answers.
December 1, 2022
The AHEAD clinical trial will assess whether the new Alzheimer’s drug, lecanemab, can delay the onset of dementia in persons who are at high risk of developing the disease. Lecanemab has aroused some excitement recently and has been covered extensively by the media. A separate Phase III clinical trial, published Nov. 29 in The New England […]
KatieCouric.com: How to Spot the Warning Signs of Brain Trauma — And Prevent the Injuries That Lead to It
November 28, 2022
Did you know you can have chronic traumatic encephalopathy (CTE) from head trauma even if you are not an athlete or have served in the military? Chronic traumatic encephalopathy (CTE) is caused by repeated traumatic brain injuries. Most people are unaware they had brain trauma and ignore symptoms of CTE unless they are in […]
November 16, 2022
Melissa Flores, LPC, NCC, counselor of the Biggs Institute, discusses how the institute’s “ReCollections” art program creates space for connection for patients and their caregivers. To read the article, visit the San Antonio Magazine.
November 14, 2022
More than 15 female UT Health San Antonio physicians were recognized as Women Leaders in Medicine for their contributions to medicine by the Bexar County Medical Society. From the Biggs Institute and collaborators of the Biggs Institute, Sudha Seshadri, MD, founding director of the Biggs Institute, and Sarah Horn, MD, neurologist, Sara E. Espinoza, MD, […]
October 7, 2022
Claudia Satizabal, PhD, researcher and assistant professor at the Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, comments on her research regarding small consumption of fatty acids may help preserve brain function. To read the full article, visit Forbes.com.